Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Related Citations for PubMed (Select 24517089)

1.

Epigenetics of prostate cancer: distribution of histone H3K27me3 biomarkers in peri-tumoral tissue.

Ngollo M, Dagdemir A, Judes G, Kemeny JL, Penault-Llorca F, Boiteux JP, Lebert A, Bignon YJ, Guy L, Bernard-Gallon D.

OMICS. 2014 Mar;18(3):207-9. doi: 10.1089/omi.2013.0117. Epub 2014 Feb 11. No abstract available.

PMID:
24517089
2.

Histone modifications and chromatin organization in prostate cancer.

Chen Z, Wang L, Wang Q, Li W.

Epigenomics. 2010 Aug;2(4):551-60. doi: 10.2217/epi.10.31. Review.

3.

[Epigenetics of prostate cancer].

Yi XM, Zhou WQ.

Zhonghua Nan Ke Xue. 2010 Jul;16(7):635-41. Review. Chinese.

PMID:
20873600
4.

Epigenetic biomarkers in prostate cancer: Current and future uses.

Chiam K, Ricciardelli C, Bianco-Miotto T.

Cancer Lett. 2014 Jan 28;342(2):248-56. doi: 10.1016/j.canlet.2012.02.011. Epub 2012 Mar 3. Review.

PMID:
22391123
5.

Epigenetics of prostate cancer.

Li LC.

Front Biosci. 2007 May 1;12:3377-97. Review.

PMID:
17485307
6.

Bisulfite sequencing of chromatin immunoprecipitated DNA (BisChIP-seq) directly informs methylation status of histone-modified DNA.

Statham AL, Robinson MD, Song JZ, Coolen MW, Stirzaker C, Clark SJ.

Genome Res. 2012 Jun;22(6):1120-7. doi: 10.1101/gr.132076.111. Epub 2012 Mar 30.

7.

Heterogeneous epigenetic regulation of TIMP3 in prostate cancer.

Shinojima T, Yu Q, Huang SK, Li M, Mizuno R, Liu ET, Hoon DS, Lessard L.

Epigenetics. 2012 Nov;7(11):1279-89. doi: 10.4161/epi.22333. Epub 2012 Sep 28.

8.

Histone trimethylation of the p53 gene by expression of a constitutively active prolactin receptor in prostate cancer cells.

Tan D, Tan S, Zhang J, Tang P, Huang J, Zhou W, Wu S.

Chin J Physiol. 2013 Oct 31;56(5):282-90. doi: 10.4077/CJP.2013.BAB139. Epub 2013 Aug 31. Erratum in: Chin J Physiol. 2013 Dec 31;56(6):362.

PMID:
24032713
9.

Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells.

Chapman-Rothe N, Curry E, Zeller C, Liber D, Stronach E, Gabra H, Ghaem-Maghami S, Brown R.

Oncogene. 2013 Sep 19;32(38):4586-92. doi: 10.1038/onc.2012.477. Epub 2012 Nov 5.

PMID:
23128397
10.

Chromatin immunoprecipitation and high-throughput sequencing from paraffin-embedded pathology tissue.

Fanelli M, Amatori S, Barozzi I, Minucci S.

Nat Protoc. 2011 Nov 10;6(12):1905-19. doi: 10.1038/nprot.2011.406.

PMID:
22082985
11.

Epigenetics in prostate cancer: biologic and clinical relevance.

Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, Shariat SF.

Eur Urol. 2011 Oct;60(4):753-66. doi: 10.1016/j.eururo.2011.06.035. Epub 2011 Jun 22. Review.

PMID:
21719191
12.

Epigenetic targets in the diagnosis and treatment of prostate cancer.

Manoharan M, Ramachandran K, Soloway MS, Singal R.

Int Braz J Urol. 2007 Jan-Feb;33(1):11-8. Review.

13.

Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells.

Xiang N, Zhao R, Song G, Zhong W.

Carcinogenesis. 2008 Nov;29(11):2175-81. doi: 10.1093/carcin/bgn179. Epub 2008 Aug 1.

14.

Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia.

Paradowska A, Fenic I, Konrad L, Sturm K, Wagenlehner F, Weidner W, Steger K.

Int J Oncol. 2009 Jul;35(1):87-96.

PMID:
19513555
15.

Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells.

Beklemisheva AA, Fang Y, Feng J, Ma X, Dai W, Chiao JW.

Anticancer Res. 2006 Mar-Apr;26(2A):1225-30.

16.

Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.

Ke XS, Qu Y, Rostad K, Li WC, Lin B, Halvorsen OJ, Haukaas SA, Jonassen I, Petersen K, Goldfinger N, Rotter V, Akslen LA, Oyan AM, Kalland KH.

PLoS One. 2009;4(3):e4687. doi: 10.1371/journal.pone.0004687. Epub 2009 Mar 5.

17.

Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.

Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold DL, Sekido Y, Huang TH, Issa JP.

Nat Genet. 2008 Jun;40(6):741-50. doi: 10.1038/ng.159. Epub 2008 May 18.

PMID:
18488029
18.

DNA methylation and histone modification regulate silencing of OPG during tumor progression.

Lu TY, Kao CF, Lin CT, Huang DY, Chiu CY, Huang YS, Wu HC.

J Cell Biochem. 2009 Sep 1;108(1):315-25. doi: 10.1002/jcb.22256.

PMID:
19565568
19.

Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer.

Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, Kikuno N, Kawakami T, Tanaka Y, Pookot D, Chen Z, Majid S, Enokida H, Nakagawa M, Dahiya R.

Clin Cancer Res. 2007 May 1;13(9):2541-8.

20.

Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer.

Pellakuru LG, Iwata T, Gurel B, Schultz D, Hicks J, Bethel C, Yegnasubramanian S, De Marzo AM.

Am J Pathol. 2012 Aug;181(2):560-9. doi: 10.1016/j.ajpath.2012.04.021. Epub 2012 Jun 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk